Executive compensation packages for chief executive officers of mega-cap pharmaceutical corporations like Pfizer consist of a fixed base salary supplemented by performance-based annual cash bonuses, stock options, and restricted stock units tied directly to long-term corporate financial metrics and shareholder return targets. While base salaries typically hover in the range of one and a half to two million dollars, total realized annual compensation frequently scales significantly higher—often reaching fifteen to twenty-five million dollars or more—depending on the successful commercialization of blockbuster drugs, successful vaccine deployments, and overall stock market performance. Detailed breakdowns of executive pay structures are published annually in the company's official proxy statements filed with regulatory bodies.